Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development.

DCVC Bio led Thursday’s round, with participation from Alpha Intelligence Capital and Hemi Ventures.

X-37 LLC is the latest in a string of JVs

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers